Published in Lancet Oncol on August 01, 2005
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics (2009) 1.40
Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol (2008) 1.33
Chemotherapy for malignant brain tumors of childhood. J Child Neurol (2008) 1.14
Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol (2011) 1.09
Initial management of childhood brain tumors: neurosurgical considerations. J Child Neurol (2008) 1.05
Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol (2011) 1.03
Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. J Clin Oncol (2012) 1.03
Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol (2009) 0.99
Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol (2012) 0.97
Aggressive infantile embryonal tumors. J Child Neurol (2008) 0.96
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol (2016) 0.95
The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr (2012) 0.94
Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children's oncology group. Cancer (2011) 0.92
Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003. Childs Nerv Syst (2006) 0.91
Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. Pediatr Neurol (2015) 0.90
Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol (2008) 0.88
M1 Medulloblastoma: high risk at any age. J Neurooncol (2008) 0.87
Advances in treatment of pediatric brain tumors. NeuroRx (2006) 0.87
Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome. PLoS One (2012) 0.87
Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. F1000Prime Rep (2014) 0.86
The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev (2008) 0.85
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. Childs Nerv Syst (2014) 0.85
Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement. Neuro Oncol (2012) 0.84
Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). Curr Treat Options Neurol (2013) 0.82
Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer (2009) 0.81
Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol Commun (2014) 0.81
Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathol Commun (2013) 0.80
Decreased morbidity and mortality of autologous hematopoietic transplants for children with malignant central nervous system tumors: the 'Head Start' trials, 1991-2009. Bone Marrow Transplant (2016) 0.80
Treatment of medulloblastoma in young children. Lancet Oncol (2005) 0.80
Viruses and human brain tumors: cytomegalovirus enters the fray. J Clin Invest (2011) 0.80
Identification of cell surface targets through meta-analysis of microarray data. Neoplasia (2012) 0.79
Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor. Cancer Res Treat (2016) 0.79
Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Arch Pathol Lab Med (2011) 0.78
Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors. Acta Neuropathol Commun (2014) 0.78
Factors affecting survival of medulloblastoma in children: the changing concept of management. Childs Nerv Syst (2015) 0.77
Medulloblastoma. J Child Neurol (2015) 0.77
Medulloblastoma in infants: the critical issues of the dilemma. Curr Oncol (2010) 0.77
A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. Oncotarget (2016) 0.76
Melanotic medulloblastoma in children. Childs Nerv Syst (2011) 0.76
Neurocognitive function in same-sex twins following focal radiation for medulloblastoma. Neuro Oncol (2007) 0.75
Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery. Surg Neurol Int (2016) 0.75
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol (2013) 0.75
Shared medical decision-making: considering what options to present based on an ethical analysis of the treatment of brain tumors in very young children. Pediatr Blood Cancer (2012) 0.75
Appraisal of the current staging system for residual medulloblastoma by volumetric analysis. Childs Nerv Syst (2011) 0.75
Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro Oncol (2016) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg (2007) 3.66
Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg (2007) 2.74
Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol (2005) 2.46
Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer (2009) 2.32
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol (2009) 2.15
Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr (2012) 2.02
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer (2007) 2.01
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 1.93
Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain (2003) 1.85
A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer (2006) 1.76
Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood (2011) 1.71
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer (2005) 1.67
Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer (2008) 1.59
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. J Neurosurg (2005) 1.56
Chiari malformation in craniosynostosis. Childs Nerv Syst (2005) 1.56
Thymus and mediastinal node involvement in childhood Langerhans cell histiocytosis: long-term follow-up from the French national cohort. Pediatr Blood Cancer (2013) 1.54
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 1.54
Mortality in children with severe head trauma: predictive factors and proposal for a new predictive scale. Neurosurgery (2010) 1.50
World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer (2008) 1.48
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol (2010) 1.48
Neurenteric cysts in children: 16 consecutive cases and review of the literature. J Neurosurg (2005) 1.48
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol (2009) 1.47
Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol (2006) 1.47
Children's views on their involvement in clinical research. Pediatr Blood Cancer (2008) 1.47
Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab (2004) 1.46
Retinoblastoma. Orphanet J Rare Dis (2006) 1.44
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer (2013) 1.43
Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report. J Pediatr Hematol Oncol (2006) 1.39
Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol (2007) 1.39
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed (2011) 1.39
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol (2003) 1.36
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study. Cancer (2011) 1.34
Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol (2003) 1.33
WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol (2009) 1.31
Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain (2007) 1.29
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer (2009) 1.26
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol (2010) 1.25
Genotype-phenotype correlations in hereditary familial retinoblastoma. Hum Mutat (2007) 1.25
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol (2010) 1.24
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res (2011) 1.24
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer (2003) 1.24
Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr (2004) 1.23
Brainstem gliomas in children and adults. Curr Opin Oncol (2008) 1.23
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol (2009) 1.20
Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol (2009) 1.20
French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol (2007) 1.20
The readability of information and consent forms in clinical research in France. PLoS One (2010) 1.19
Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome. Cancer (2003) 1.19
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer (2001) 1.18
Chemothermotherapy in the management of retinoblastoma. Ophthalmology (2002) 1.16
Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol (2011) 1.16
Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys (2007) 1.16
Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol (2005) 1.15
Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg (2002) 1.14
Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol (2010) 1.13
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol (2005) 1.13
Neonatal cancer. Lancet Oncol (2013) 1.13
Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol (2003) 1.12
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer (2005) 1.12
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med (2009) 1.12
Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer (2008) 1.12
Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS (2008) 1.11
Surgical treatment of epilepsy in Sturge-Weber syndrome in children. J Neurosurg (2007) 1.11
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer (2005) 1.10